Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82344 | 0.85 | HDAC1 (0.35) | LMNAL3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5016201 | 0.81 | L3MBTL1 (0.42) | LMNAL3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL83768 | 0.81 | NPSR1 (0.36) | LMNAL3MBTL1MEN1KMT2AHDAC1 | |
| SCHEMBL5014878 | 0.79 | HDAC6 (0.34) | LMNAL3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5015654 | 0.79 | MEN1 (0.34) | LMNAL3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5014071 | 0.79 | NPSR1 (0.34) | L3MBTL1MEN1KMT2AHDAC1HDAC6 | |
| SCHEMBL83292 | 0.78 | GSK3A (0.36) | SMN1; SMN2HDAC1HDAC6CCNE2CCNE1 | |
| SCHEMBL5028848 | 0.78 | JAK2 (0.38) | SMN1; SMN2HDAC1HDAC6CCNE2CCNE1 | |
| SCHEMBL83895 | 0.77 | MEN1 (0.42) | MEN1KMT2ASMN1; SMN2HDAC1HDAC6 | |
| SCHEMBL5027073 | 0.76 | CCNE2 (0.35) | HDAC1HDAC6CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PDPK1 | LMNA 4459/4885L3MBTL1 4035/4885MEN1 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.